Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)¶
Why this mattered¶
UKPDS 33 changed type 2 diabetes from a disease managed mainly by symptom control into one managed by evidence-based risk reduction. In newly diagnosed patients followed for a median of about 10 years, intensive therapy with sulphonylureas or insulin lowered median HbA1c from 7.9% to 7.0% and reduced “any diabetes-related endpoint” by 12%, driven chiefly by a 25% reduction in microvascular endpoints such as need for retinal photocoagulation. This gave clinicians randomized evidence that chronic hyperglycemia itself was a modifiable cause of blindness, kidney disease, and other small-vessel complications in type 2 diabetes, not merely a biochemical marker.
Its importance was also in what it did not prove. Intensive glucose lowering did not significantly reduce diabetes-related death, all-cause mortality, or macrovascular disease in the trial, and it increased hypoglycemia and weight gain. That boundary shaped the next two decades: HbA1c targets became central to diabetes care, but later studies had to ask how low to go, in whom, and by what means. The paper therefore set both the standard and the caution for modern diabetes therapeutics: glucose control prevents microvascular harm, but cardiovascular and renal protection require broader strategies.
Subsequent breakthroughs built around this framework. UKPDS follow-up studies strengthened the idea of a long-term “legacy effect” from early glycemic control, while later cardiovascular-outcome trials for GLP-1 receptor agonists and SGLT2 inhibitors addressed the macrovascular and renal questions that UKPDS 33 left unresolved. In that sense, UKPDS 33 made intensive glycemic control a foundation of type 2 diabetes care, and also made clear that glucose lowering alone could not be the whole paradigm.
Abstract¶
(no abstract available)
Related¶
- cite → The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus — UKPDS 33 cites the DCCT trial as prior evidence that intensive glycemic control reduces long-term diabetic complications.
- cite ← Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin — The Diabetes Prevention Program cites UKPDS 33 to connect diabetes prevention with the established importance of glycemic control for reducing type 2 diabetes complications.
- enables ← The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus — The DCCT established intensive glycemic control as a complication-reducing intervention, enabling UKPDS to test the same clinical claim in type 2 diabetes.